SpectraScience, Inc. Retains Quorum Consulting, Inc.

SAN DIEGO, CA--(Marketwire - May 05, 2010) - SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company, announced today that it has retained San Francisco based Quorum Consulting to assist in the proper design of current and future clinical trials.

Jim Hitchin, SpectraScience CEO, stated, "Safety and effectiveness are no longer the only standards to measure product potential. Third-party payers and governmental agencies in the US, Europe, and Asia also want to know the impact of new technologies on budgets and patient outcomes outside of the clinical trials. Quorum's health economics and outcomes group supplement our R&D activities by designing, operating, and publishing studies to demonstrate benefits that are of the greatest interest to our customers."

"Also, obtaining coverage and reimbursement for our new technology requires an innovative strategic plan and tactical expertise. Quorum will help us determine whether existing billing codes are appropriate for our products. They will evaluate whether coverage is available and how studies should be designed to minimize coverage barriers. In addition, they will determine the exact reimbursement amount paid to hospitals, physicians, and work to change payment rates if reimbursement is not adequate."

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT® Optical Biopsy System and LUMA® Cervical Imaging Systems. These devices are used to assess tissue quickly to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: Medical Devices Cancer Screening Optical Biopsy Barrett’s